Frank Thompson
If you’ve been watching Wegovy or Zepbound prices climb and hoping Medicare would jump in, this is it. Starting July 1, 2026, Medicare’s rolling out something it’s never done before: coverage for GLP-1 weight-loss drugs at a flat $50 monthly copay for eligible people. That beats the $149 to $699 per month most people pay out of pocket by a mile, and the specifics matter enough to understand now before you call your doctor.
What the GLP-1 Bridge Program Actually Is
| Medication | Form(s) Covered | Monthly Cost Without Program | Monthly Copay (Bridge Program) |
|---|---|---|---|
| Wegovy | Pill and injection | $149-$699 | $50 |
| Zepbound | KwikPen only | $149-$699 | $50 |
| Foundayo (orforglipron) | Oral tablet | $149-$699 | $50 |
The Medicare GLP-1 Bridge Program runs from July 1, 2026 through December 31, 2027. It’s a limited-time test, not a permanent benefit. CMS is collecting data to see what happens when Medicare covers obesity drugs.
The $50 copay gets the headlines, but the fine print determines whether you actually benefit. Three medications are covered. Wegovy comes in pill and injection forms, both covered. Zepbound is covered only through the KwikPen, not the single-use pens or vials. Then there’s Foundayo (orforglipron), an oral tablet.
If you’ve been using Zepbound in a different format, switch that expectation now. Without this program, you’re looking at anywhere from $149 to $699 monthly according to GoodRx. For people on fixed incomes, that’s impossible to sustain. The $50 copay changes everything.
Who Qualifies and What You’ll Need from Your Doctor
You need to be in a Part D plan (either standalone or through Medicare Advantage). Your BMI has to be 27 or higher. And you need at least one qualifying condition: heart disease, prediabetes, that kind of thing.
This isn’t open to everyone with obesity. CMS designed it to target people whose weight is driving actual health problems. Your doctor documents the diagnosis and BMI, but here’s where it diverges from a normal prescription.
Prior authorization doesn’t go through your usual Part D process. It flows through a central CMS contractor system run by Humana. Your doctor’s office may need to submit paperwork to a place they’ve never sent it before. Call ahead in June to confirm your provider knows the process. The last thing you want is delays on your first fill.
The Bigger Picture: Why This Is Happening Now
Medicare was legally barred from covering weight-loss drugs since the 2003 Medicare Modernization Act. That changed when the clinical evidence shifted. Drugs like Wegovy and Zepbound aren’t just prescribed for weight loss anymore. The SELECT trial showed cardiovascular benefits for people with obesity taking semaglutide, giving CMS the cover it needed.
Here’s the uncertain part: the road after 2027. CMS had planned a follow-on program called the BALANCE Model, which would’ve let Part D plans voluntarily include these drugs starting January 2027. NPR reported in May 2026 that it’s been delayed indefinitely. So the Bridge Program is your only Medicare pathway for obesity GLP-1s through the end of 2027. Nobody’s said what happens after. Keep that in mind if you’re betting on long-term coverage.
What to Do Between Now and July 1
Confirm your Part D enrollment first. If you’re in Medicare Advantage, verify it includes drug coverage (sometimes called MAPD). Medicare.gov has a plan finder tool.
Talk to your doctor next. Ask if your health conditions, BMI, and history would qualify you. Have them document the qualifying diagnosis now so they’re not scrambling later. If they’re unclear about the Humana authorization process, the contractor will have provider resources.
The $50 copay applies across all income brackets under current program design. People with Extra Help (the Low Income Subsidy) might pay less, but that’s still being clarified in some places. Ask your plan directly.
A Few Things to Keep Realistic Expectations About
Early program launches get bumpy. The Humana authorization system is new, and first fills always involve delays while pharmacies, doctors, and insurers figure out their roles. That’s not a reason to wait, just a reason to expect some friction.
These medications work best paired with lifestyle changes. They’re powerful, but they’re not magic. Your doctor is the right person to decide if one fits your situation.
The Bridge Program is genuinely historic for Medicare. For millions of Part D enrollees, July 1 opens an actual door. Spend the next six months getting the details straight, talking to your doctor, and checking your coverage. The $50 copay is real, but only if you meet the eligibility requirements and get through the authorization process correctly. Call 1-800-MEDICARE (1-800-633-4227) or visit Medicare.gov if you need help with your specific plan before July.
Sources
- GLP-1 Weight-Loss Drug Demonstration Begins July 2026, Medicare Rights Center (June 4, 2026)
- Medicare to Launch Weight Loss Drug Option in July with $50 Copay, NPR (May 6, 2026)
- Medicare and Weight-Loss Drugs: Coverage Expansion in 2026, GoodRx (June 2026)
- Updated: Medicare Part D Coverage for GLP-1 Drugs in 2026, United Medicare Advisors (June 2026)
- Does Medicare Cover GLP-1 Weight Loss Drugs?, Humana (June 8, 2026)
This article is for informational purposes only. Medicare rules change annually. Always verify current plan details at Medicare.gov or by calling 1-800-MEDICARE (1-800-633-4227). This site does not sell insurance or recommend specific plans.
Recommended Resources
Disclosure: As an Amazon Associate, we earn a small commission from qualifying purchases at no extra cost to you. We only recommend products that genuinely support the topics covered in this article.
- Medicare For Dummies (~$22), The definitive consumer guide to Medicare, enrollment windows, Part A/B/C/D, and supplement plans.
- Get What’s Yours for Medicare (~$17), Maximize your Medicare benefits and minimize out-of-pocket costs. Covers Part D drug coverage gaps and Medigap in depth.
